Weight loss jabs do not slow Alzheimer's disease as hoped, causing firm's share prices to plummet ⊕⊕
found
a story from The Daily Mail 💩 › The Daily Mail
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novo Nordisk had hoped to repurpose semaglutide - the active ingredient in its Wegovy and Ozempic jabs - as a groundbreaking dementia treatment after seeing early encouraging signs.